Conclusions
PERTUSSIS, HIB
The study demonstrated that the investigational DTwP-HepB-Hib vaccine formulation was non-inferior to the licensed comparator DTwP-HepB-Hib vaccine formulation both in terms of HepB seroprotection rate and in terms of pertussis immune responses. The immune responses to all the antigens (D, T, P, HepB and Hib) in both the DTwP-HepB-Hib vaccine formulations were also similar.Overall, vaccination with either the investigational or the licensed comparator DTwP-HepB-Hib vaccine formulation was found to be well tolerated among the infants administered the 3-dose vaccine primary series (at 6–8 weeks, 10–12 weeks and 14–16 weeks of age) along with other age-recommended vaccines.